Your browser doesn't support javascript.
loading
Development and testing of a polygenic risk score for breast cancer aggressiveness.
Shieh, Yiwey; Roger, Jacquelyn; Yau, Christina; Wolf, Denise M; Hirst, Gillian L; Swigart, Lamorna Brown; Huntsman, Scott; Hu, Donglei; Nierenberg, Jovia L; Middha, Pooja; Heise, Rachel S; Shi, Yushu; Kachuri, Linda; Zhu, Qianqian; Yao, Song; Ambrosone, Christine B; Kwan, Marilyn L; Caan, Bette J; Witte, John S; Kushi, Lawrence H; 't Veer, Laura van; Esserman, Laura J; Ziv, Elad.
Affiliation
  • Shieh Y; Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA. yis4001@med.cornell.edu.
  • Roger J; PhD Program in Biological and Medical Informatics, University of California, San Francisco, San Francisco, CA, USA.
  • Yau C; Department of Surgery, University of California, San Francisco, San Francisco, CA, USA.
  • Wolf DM; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Hirst GL; Department of Surgery, University of California, San Francisco, San Francisco, CA, USA.
  • Swigart LB; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Huntsman S; Division of General Internal Medicine, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Hu D; Division of General Internal Medicine, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Nierenberg JL; Division of General Internal Medicine, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Middha P; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.
  • Heise RS; Division of General Internal Medicine, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Shi Y; Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.
  • Kachuri L; Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.
  • Zhu Q; Department of Epidemiology and Population Health, Stanford University, Stanford, CA, USA.
  • Yao S; Department of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, NY, USA.
  • Ambrosone CB; Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Kwan ML; Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Caan BJ; Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
  • Witte JS; Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
  • Kushi LH; Department of Epidemiology and Population Health, Stanford University, Stanford, CA, USA.
  • 't Veer LV; Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
  • Esserman LJ; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Ziv E; Department of Surgery, University of California, San Francisco, San Francisco, CA, USA.
NPJ Precis Oncol ; 7(1): 42, 2023 May 15.
Article in En | MEDLINE | ID: mdl-37188791
ABSTRACT
Aggressive breast cancers portend a poor prognosis, but current polygenic risk scores (PRSs) for breast cancer do not reliably predict aggressive cancers. Aggressiveness can be effectively recapitulated using tumor gene expression profiling. Thus, we sought to develop a PRS for the risk of recurrence score weighted on proliferation (ROR-P), an established prognostic signature. Using 2363 breast cancers with tumor gene expression data and single nucleotide polymorphism (SNP) genotypes, we examined the associations between ROR-P and known breast cancer susceptibility SNPs using linear regression models. We constructed PRSs based on varying p-value thresholds and selected the optimal PRS based on model r2 in 5-fold cross-validation. We then used Cox proportional hazards regression to test the ROR-P PRS's association with breast cancer-specific survival in two independent cohorts totaling 10,196 breast cancers and 785 events. In meta-analysis of these cohorts, higher ROR-P PRS was associated with worse survival, HR per SD = 1.13 (95% CI 1.06-1.21, p = 4.0 × 10-4). The ROR-P PRS had a similar magnitude of effect on survival as a comparator PRS for estrogen receptor (ER)-negative versus positive cancer risk (PRSER-/ER+). Furthermore, its effect was minimally attenuated when adjusted for PRSER-/ER+, suggesting that the ROR-P PRS provides additional prognostic information beyond ER status. In summary, we used integrated analysis of germline SNP and tumor gene expression data to construct a PRS associated with aggressive tumor biology and worse survival. These findings could potentially enhance risk stratification for breast cancer screening and prevention.

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: NPJ Precis Oncol Year: 2023 Document type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: NPJ Precis Oncol Year: 2023 Document type: Article Affiliation country: United States